Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | NYSE | Salute | Prodotti farmaceutici | 737,42 Mrd USD | 88,5x | 8,35 | 818,56 USD | -1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 24% Rialzo | Fai l’upgrade a Pro+ | |
Novo Nordisk ADR | NYSE | Salute | Prodotti farmaceutici | 497,27 Mrd USD | 38,4x | 1,11 | 112,04 USD | 0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 36,4% Rialzo | Fai l’upgrade a Pro+ | |
J&J | NYSE | Salute | Prodotti farmaceutici | 385,60 Mrd USD | 26,3x | -0,48 | 160,15 USD | 0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 8,7% Rialzo | Fai l’upgrade a Pro+ | |
AbbVie | NYSE | Salute | Prodotti farmaceutici | 360,03 Mrd USD | 71,3x | -1,63 | 203,39 USD | -0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 3,3% Rialzo | Fai l’upgrade a Pro+ | |
Roche Holding ADR | OTC Markets | Salute | Prodotti farmaceutici | 273,86 Mrd USD | 22,5x | -6,57 | 39,37 USD | 1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 22,1% Rialzo | Fai l’upgrade a Pro+ | |
Roche Holding Participation | OTC Markets | Salute | Prodotti farmaceutici | 273,86 Mrd USD | 22,5x | -6,57 | 312,59 USD | 1,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Merck&Co | NYSE | Salute | Prodotti farmaceutici | 258,45 Mrd USD | 21,3x | 0,06 | 101,96 USD | -0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 32,9% Rialzo | Fai l’upgrade a Pro+ | |
AstraZeneca PLC | OTC Markets | Salute | Prodotti farmaceutici | 221,18 Mrd USD | 34,3x | 8,48 | 142,85 USD | 0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
AstraZeneca ADR | NASDAQ | Salute | Prodotti farmaceutici | 221,18 Mrd USD | 34,3x | 8,48 | 71,37 USD | 0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 27,9% Rialzo | Fai l’upgrade a Pro+ | |
Novartis | OTC Markets | Salute | Prodotti farmaceutici | 219,50 Mrd USD | 12,7x | 0,19 | 106,16 USD | -2,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -24% Ribasso | Fai l’upgrade a Pro+ | |
Novartis ADR | NYSE | Salute | Prodotti farmaceutici | 219,50 Mrd USD | 12,7x | 0,19 | 109,36 USD | 0,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10,7% Rialzo | Fai l’upgrade a Pro+ | |
Thermo Fisher Scientific | NYSE | Salute | Attrezzature e forniture medicali | 213,16 Mrd USD | 34,9x | 7,57 | 557,56 USD | 2,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 19,9% Rialzo | Fai l’upgrade a Pro+ | |
Abbott Labs | NYSE | Salute | Attrezzature e forniture medicali | 206,87 Mrd USD | 36,2x | 2,87 | 118,66 USD | 4,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 14,7% Rialzo | Fai l’upgrade a Pro+ | |
Intuitive Surgical | NASDAQ | Salute | Attrezzature e forniture medicali | 180,46 Mrd USD | 79,9x | 1,75 | 506,04 USD | 0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 8,9% Rialzo | Fai l’upgrade a Pro+ | |
Danaher | NYSE | Salute | Attrezzature e forniture medicali | 179,04 Mrd USD | 47x | -1,33 | 248,13 USD | 1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 17,2% Rialzo | Fai l’upgrade a Pro+ | |
Amgen | NASDAQ | Salute | Prodotti farmaceutici | 171,67 Mrd USD | 40,5x | -0,89 | 318,86 USD | -0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 6% Rialzo | Fai l’upgrade a Pro+ | |
Pfizer | NYSE | Salute | Prodotti farmaceutici | 159,40 Mrd USD | 37,6x | 0,55 | 28,07 USD | -0,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 14,8% Rialzo | Fai l’upgrade a Pro+ | |
Stryker | NYSE | Salute | Attrezzature e forniture medicali | 139,89 Mrd USD | 38,9x | 1,46 | 366,51 USD | 2,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 12,3% Rialzo | Fai l’upgrade a Pro+ | |
Sanofi ADR | NASDAQ | Salute | Prodotti farmaceutici | 134,25 Mrd USD | 27,9x | -0,55 | 53,22 USD | 0,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 19,1% Rialzo | Fai l’upgrade a Pro+ | |
Boston Scientific | NYSE | Salute | Attrezzature e forniture medicali | 123,49 Mrd USD | 68,8x | 1,47 | 83,81 USD | -0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 16,6% Rialzo | Fai l’upgrade a Pro+ | |
Vertex | NASDAQ | Salute | Ricerca medica e biotecnologica | 121,50 Mrd USD | -247,7x | 2,19 | 470,72 USD | -1,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 8,8% Rialzo | Fai l’upgrade a Pro+ | |
Medtronic | NYSE | Salute | Attrezzature e forniture medicali | 115,76 Mrd USD | 30,4x | 3,09 | 90,08 USD | 0,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 7,6% Rialzo | Fai l’upgrade a Pro+ | |
Gilead | NASDAQ | Salute | Prodotti farmaceutici | 111,31 Mrd USD | 105,9x | -1,3 | 89,44 USD | 0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 1,3% Rialzo | Fai l’upgrade a Pro+ | |
Bristol-Myers Squibb | NYSE | Salute | Prodotti farmaceutici | 110,47 Mrd USD | -15,3x | 0,09 | 54,31 USD | -2,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -2,3% Ribasso | Fai l’upgrade a Pro+ | |
Essilor International SA | OTC Markets | Salute | Attrezzature e forniture medicali | 107,25 Mrd USD | 42,7x | -12,41 | 117,24 USD | 0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 3,8% Rialzo | Fai l’upgrade a Pro+ | |
Elevance Health | NYSE | Salute | Fornitori e servizi sanitari | 96,19 Mrd USD | 15,1x | 1,68 | 414,63 USD | 2,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 30,4% Rialzo | Fai l’upgrade a Pro+ | |
HCA | NYSE | Salute | Fornitori e servizi sanitari | 92,31 Mrd USD | 15,8x | 1,7 | 357,18 USD | -0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 12,5% Rialzo | Fai l’upgrade a Pro+ | |
Regeneron Pharma | NASDAQ | Salute | Ricerca medica e biotecnologica | 90,63 Mrd USD | 19,5x | 839,78 USD | 0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 37,4% Rialzo | Fai l’upgrade a Pro+ | ||
CSL | OTC Markets | Salute | Prodotti farmaceutici | 89,64 Mrd USD | 33,9x | 1,75 | 93,02 USD | -0,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 17,3% Rialzo | Fai l’upgrade a Pro+ | |
Cigna | NYSE | Salute | Fornitori e servizi sanitari | 88,08 Mrd USD | 24,6x | -0,56 | 315,99 USD | 0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 27,1% Rialzo | Fai l’upgrade a Pro+ |